Coronavirus disease (C-19) has led to a global pandemic since its emergence in December 2019. The majority of research into C-19 has focused on transmission, and mortality and morbidity associated with the virus. However, less attention has been given to its impact on patients with persistent spinal pain syndrome type II (PSPS type II) supplied with spinal cord stimulation (SCS) or intrathecal morphine pump (ITMP).

A single-center retrospective analysis of 86 patients with PSPS type II was performed. Medical records were analyzed from all patients treated with SCS and ITMP before C-19. Pain intensity (NRS), generic health status (EQ-5D-5L), Becks Depressions Inventory (BDI-V), and Pain Catastrophizing Scale (PCS) were assessed before as well as during the global pandemic. Further, the participants completed a self-designed C-19 questionnaire. Statistical analysis was performed using Mann-Whitney U and Wilcoxon rank-sum test.

In total, 43 patients with complete datasets were included in the final analysis. During C-19 there was a significant deterioration in the EQ5D5L (p=0.004) and BDI-V (p=0.001). There were no significant differences for NRS and PDI. Fear of C-19 infection could be seen as a significant predictor of NRS deterioration (p=0.032). 44% patients were affected by C-19 itself. No more subjective pain was reported during C-19 (88%), 84% saw no change in pain perception. Fear of a vaccination was denied by 88%. 40% of patients felt isolated. The majority of the patients did not state that doctors were less accessible (88%). Relationship status and media use had no influence on the outcome parameters.

The results of this study showed a significant worsening of quality of life and depressive symptoms during the pandemic in patients with PSPS type II. Fear of C-19 could be seen as a negative predictive factor for pain perception. Neurosurgical pain patients were able to reach their therapists easily despite the pandemic.